MA32929B1 - Lactames en tant qu'inhibiteurs de bêta-sécrétase - Google Patents

Lactames en tant qu'inhibiteurs de bêta-sécrétase

Info

Publication number
MA32929B1
MA32929B1 MA33879A MA33879A MA32929B1 MA 32929 B1 MA32929 B1 MA 32929B1 MA 33879 A MA33879 A MA 33879A MA 33879 A MA33879 A MA 33879A MA 32929 B1 MA32929 B1 MA 32929B1
Authority
MA
Morocco
Prior art keywords
lactamate
beta
acts
secretase inhibitors
compounds
Prior art date
Application number
MA33879A
Other languages
Arabic (ar)
English (en)
Inventor
Brian Thomas O'neill
Michael Aaron Brodney
Ivan Viktorovich Efremov
Christopher John Helal
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41481076&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32929(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MA32929B1 publication Critical patent/MA32929B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des composés et des sels de qualité pharmaceutique des composés, les composés présentant la structure représentée par la Formule (I) telle que définie dans la description. La présente invention concerne également des compositions pharmaceutiques, des méthodes de traitement, des méthodes de synthèse et des intermédiaires.
MA33879A 2008-11-23 2009-11-12 Lactames en tant qu'inhibiteurs de bêta-sécrétase MA32929B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11722508P 2008-11-23 2008-11-23
PCT/IB2009/055043 WO2010058333A1 (fr) 2008-11-23 2009-11-12 Lactames en tant qu'inhibiteurs de bêta-sécrétase

Publications (1)

Publication Number Publication Date
MA32929B1 true MA32929B1 (fr) 2012-01-02

Family

ID=41481076

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33879A MA32929B1 (fr) 2008-11-23 2009-11-12 Lactames en tant qu'inhibiteurs de bêta-sécrétase

Country Status (28)

Country Link
US (1) US20110224231A1 (fr)
EP (1) EP2370439A1 (fr)
JP (2) JP4932065B2 (fr)
KR (1) KR20110086769A (fr)
CN (1) CN102317289A (fr)
AP (1) AP2011005725A0 (fr)
AU (1) AU2009318855A1 (fr)
BR (1) BRPI0922799A2 (fr)
CA (1) CA2743584A1 (fr)
CL (1) CL2011001147A1 (fr)
CO (1) CO6361924A2 (fr)
CR (1) CR20110269A (fr)
CU (1) CU20110113A7 (fr)
DO (1) DOP2011000134A (fr)
EA (1) EA201170722A1 (fr)
EC (1) ECSP11011073A (fr)
GE (1) GEP20135806B (fr)
IL (1) IL212869A0 (fr)
MA (1) MA32929B1 (fr)
MX (1) MX2011005346A (fr)
NI (1) NI201100096A (fr)
NZ (1) NZ592823A (fr)
PE (1) PE20110777A1 (fr)
SV (1) SV2011003916A (fr)
TN (1) TN2011000252A1 (fr)
UA (1) UA99787C2 (fr)
WO (1) WO2010058333A1 (fr)
ZA (1) ZA201103738B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074466A1 (es) 2008-12-05 2011-01-19 Sanofi Aventis Piperidina espiro pirrolidinona y piperidinona sustituidas y su uso terapeutico en enfermedades mediadas por la modulacion de los receptores h3.
EA020875B1 (ru) 2009-03-13 2015-02-27 Вайтаи Фармасьютиклз, Инк. Ингибиторы бета-секретазы
BR112012008346B1 (pt) 2009-09-11 2021-12-21 Vivoryon Therapeutics N.V. Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica
ES2689149T3 (es) 2011-01-25 2018-11-08 Bayer Cropscience Ag Procedimiento para la preparación de derivados de 1-H-pirrolidin-2,4-diona
WO2012172449A1 (fr) 2011-06-13 2012-12-20 Pfizer Inc. Lactames convenant comme inhibiteurs des bêta-sécrétases
TWI557112B (zh) * 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
EP2900650A1 (fr) 2012-09-28 2015-08-05 Vitae Pharmaceuticals, Inc. Inhibiteurs de beta-secrétase
WO2016008064A1 (fr) * 2014-07-14 2016-01-21 Merck Sharp & Dohme Corp. Inhibiteurs du canal potassique médullaire externe rénal
BR112016029065A2 (pt) 2014-07-14 2017-08-22 Merck Sharp & Dohme ?composto, composição farmacêutica, e, uso de um composto?
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
CN113045484B (zh) * 2019-12-27 2024-01-26 南京药石科技股份有限公司 一种2-氨基-2-(1-甲基-4-哌啶基)丙烷-1-醇的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876260A (en) * 1987-10-28 1989-10-24 State Of Israel, Israel Institute Of Biological Research Oxathiolanes
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
FR2824901B1 (fr) * 2001-05-21 2003-09-12 Poudres & Explosifs Ste Nale Procede et installation de destruction de fusee montee sur une munition
MXPA06007210A (es) * 2003-12-22 2006-08-18 Schering Corp Composiciones farmaceuticas.
US7481034B2 (en) * 2004-02-17 2009-01-27 Herm. Sprenger Gmbh & Co. Kg Double-jointed horse bit
US7659264B2 (en) * 2004-10-07 2010-02-09 Merck Sharp & Dohme Corp. CGRP receptor antagonists
WO2006044497A2 (fr) * 2004-10-13 2006-04-27 Merck & Co., Inc. Composes de spiropiperidine utilises comme inhibiteurs de beta-secretase en vue du traitement de la maladie d'alzheimer
GB0504556D0 (en) * 2005-03-04 2005-04-13 Pfizer Ltd Novel pharmaceuticals
CA2608718A1 (fr) * 2005-05-18 2006-11-23 Pfizer Limited Derives de 1, 2, 4-triazole en tant qu'antagonistes de la vasopressine
WO2007011810A1 (fr) * 2005-07-18 2007-01-25 Merck & Co., Inc. Inhibiteurs de beta-secretase de spiropiperidine destines au traitement de la maladie d'alzheimer
RU2382589C2 (ru) * 2005-09-20 2010-02-27 Ска Хайджин Продактс Аб Распределительное устройство
AU2007267983B2 (en) * 2006-05-26 2010-12-09 Eisai R&D Management Co., Ltd Imidazoazepinone compounds
EP2021003B1 (fr) * 2006-05-26 2010-07-21 Eisai R&D Management Co., Ltd. Composés d'imidazo-azéphinone
US8124613B2 (en) * 2006-06-14 2012-02-28 Virochem Pharma Inc. Spirotropane compounds
AU2007293416A1 (en) * 2006-09-07 2008-03-13 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease
JP2010505833A (ja) * 2006-10-06 2010-02-25 メルク エンド カムパニー インコーポレーテッド アルツハイマー病を治療するためのマクロ環式スピロピペリジンβ−セクレターゼ阻害剤
AU2007314338A1 (en) * 2006-10-30 2008-05-08 Merck & Co., Inc. Spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's Disease

Also Published As

Publication number Publication date
CL2011001147A1 (es) 2011-09-30
KR20110086769A (ko) 2011-07-29
ECSP11011073A (es) 2011-06-30
JP2012107029A (ja) 2012-06-07
JP2012509310A (ja) 2012-04-19
GEP20135806B (en) 2013-04-10
SV2011003916A (es) 2011-07-28
CO6361924A2 (es) 2012-01-20
JP4932065B2 (ja) 2012-05-16
AU2009318855A1 (en) 2010-05-27
US20110224231A1 (en) 2011-09-15
NI201100096A (es) 2011-10-31
ZA201103738B (en) 2012-01-25
PE20110777A1 (es) 2011-10-29
EP2370439A1 (fr) 2011-10-05
UA99787C2 (en) 2012-09-25
WO2010058333A1 (fr) 2010-05-27
AP2011005725A0 (en) 2011-06-30
CU20110113A7 (es) 2012-01-31
NZ592823A (en) 2012-12-21
TN2011000252A1 (fr) 2012-12-17
EA201170722A1 (ru) 2011-10-31
CN102317289A (zh) 2012-01-11
CR20110269A (es) 2011-07-04
DOP2011000134A (es) 2011-07-31
CA2743584A1 (fr) 2010-05-27
IL212869A0 (en) 2011-07-31
BRPI0922799A2 (pt) 2019-09-24
MX2011005346A (es) 2011-06-16

Similar Documents

Publication Publication Date Title
MA32929B1 (fr) Lactames en tant qu'inhibiteurs de bêta-sécrétase
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA37886A1 (fr) Nouvelles pyridinones bicycliques
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
MA30291B1 (fr) Derives de l'azolopyridin-3-one en tant qu'inhibiteurs de la lipase endotheliale
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
MA33731B1 (fr) Inhibiteurs du virus de l'hépatite c
MA31296B1 (fr) Derives d'imidazolidine carboxamide en tant qu'inhibiteurs de lipase et de phospholipase
MA32727B1 (fr) Pyrazolylaminopyridines au titre d'inhibiteurs de fak
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
MA29857B1 (fr) Derives de triazolopyridine en tant qu'inhibiteurs de lipases et phospholipases
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
MA32887B1 (fr) Aminotetrahydropyranes en tant qu'inhibiteurs de dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA33238B1 (fr) Composés utilisés comme antagonistes de la bradykinine b1
EA201001733A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
MA34896B1 (fr) Inhibiteurs du virus de l'hepatite c
MA32903B1 (fr) Inhibiteurs de proteine-kinases
EA201070988A1 (ru) Противовирусные терапевтические средства
MA32150B1 (fr) Inhibiteurs heterocycliques de la stearoyl-coa desaturase
AR084433A1 (es) Inhibidores de la faah y composiciones farmaceuticas que los contienen
MA37891A1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble